source
- Gilead's HIV prevention shot Yeztugo posts $232 million Q2 sales, beating forecastsGilead reported that its biannual injectable for HIV pre‑exposure prophylaxis, Yeztugo, generated $232 million in revenue during the second quarter. This figure exceeds analysts' consensus estimat…
- Emergent BioSolutions cuts 93 jobs and eliminates chief medical officer role in new restructuring planEmergent BioSolutions announced a new round of restructuring aimed at aligning the company with current business realities, disclosed alongside its second‑quarter earnings. The plan includes layin…